Humira takes over ‘uveitis’ as well with versatility
‘Humira(generic name: adalimumab),’ the most well-known TNF(tumor necrosis factor)-α inhibitor and a chronic immune disorder treatment having 14 Korean indications in Korea, has attracted attention of the industry as recently getting the health insurance benefit on intractable non-infectious uvei...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.